First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly ...

Zoetis Inc. today announced that Health Canada has approved Portelatm (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months ...

GREEN BAY (WLUK) – A judge rejected the request by two murder suspects who wanted to be tried together. However, with evidence in the case still coming in, their December trials have been postponed.

GLP-1 Weight-Loss Drug in Pill Form Shows Promise in Trial By Ernie Mundell HealthDay ReporterTUESDAY, Nov. 25, 2025 (HealthDay News) — New clinical trial results bode well for what could be the first ...

As Bangladesh’s National Security Advisor Khalilur Rahman arrived in New Delhi on Tuesday (November 18, 2025), and Dhaka prepares a ‘note verbale’, the Indian government is considering its response to ...

Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain ...

BOCA RATON, FL, Nov. 19, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first US public company with a treasury strategy built to accumulate and compound Solana ...

Escalating pressures in clinical trials are amplifying long-standing issues related to growing complexity, costs, and extended timelines, putting greater burdens on sponsors, sites, and patients. The ...

Details of a new UK clinical trial to assess the risks and benefits of puberty-blocking drugs in children who question their gender have been announced. It follows the banning of the drugs for gender ...

Current GLP-1 weight-loss meds need to be taken as injections, but new trial results suggest a GLP-1 in pill form could be near In an 18-month clinical trial, people with obesity and diabetes lost ...

The global T-Cell lymphoma therapeutics market size was valued at US$ 2.3 Bn in 2024 and is projected to reach US$ 5.7 Bn by ...

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive In the pivotal Phase 3 Vivacity-MG3 and ...